Identifying reliable biomarkers is less than half the battle in the search for the first DMOAD, as the industry's drug development pathway is especially difficult relative to this disease.
Thus, we need to view OA as a disease of the entire joint as we apply our various potential biomarker techniques to identify those patients at risk for accelerated progression, and to ensure better success in clinical trials of emerging DMOAD candidates.
Efforts to identify disease-modifying osteoarthritis drugs (DMOADs
) have been hampered by several factors, but the focus has now shifted toward the validation of chemical and imaging biomarkers that should aid in DMOAD
This article aims at providing a global perspective of the issues related to DMOAD
approaches used in clinics today, as well as an update on the current strategies for developing a new generation of disease-modifying drugs and agents.
Further evaluation of MIV-711 in longer and larger DMOAD
trials is therefore warranted.
Most interest in DMOAD
development has focused on molecular events within articular cartilage (Fig.
According to the company, previous results from a phase IIa study showed that MIV-711 demonstrated benefit on joint structure and thereby has the potential to act as a disease-modifying osteoarthritis drug (DMOAD
In conjunction, the results from the company's previously phase IIa study showed that MIV-711 demonstrated benefit on joint structure and thereby has the potential to act as a disease-modifying osteoarthritis drug (DMOAD
According to the company, MIV-711 is being developed to slow or reverse the progressive degeneration of joints affected by osteoarthritis and is therefore referred to as a Disease Modifying Osteoarthritis Drug (DMOAD
), representing a very large and attractive market opportunity.
2) Farmacos modificadores de la osteoartritis (DMOADs
These drugs, known as disease-modifying osteoarthritis drugs (DMOADs
), present the properties of reversing, stabilizing, or at least delaying the course of OA.
Radiographic measurement of JSN is currently recommended within the guidance documents of the FDA and the European Agency for the Evaluation of Medicinal Products (EMEA) as the imaging end point for clinical trials of disease-modifying OA drugs (DMOADs